Rusnano Capital LLC teamed up with New York-based I2BF Global Ventures to invest $150 million in nanotechnologies for Russia’s agriculture and water industries. Rusnano Capital, a unit of Russia’s state-owned OAO Rusnano, and clean-technology investor I2BF started a seven-year fund to invest in international businesses whose applications can be used in Russia, they said in an e-mailed statement. The I2BF-RNC Strategic Resources Fund, with a target size of $150 million, has $53 million already committed.
http://www.rusnano.com
Spire Corporation (NASDAQ: SPIR) reported revenues from continuing operations for the second-quarter ended June 30, 2012 of $6.6 million, a 52% decrease from $13.9 million for the same quarter of 2011. This decline is primarily due to a decrease of $7.3 million in individual module equipment units delivered during the second-quarter of fiscal year 2012 as overcapacity in the global market continues to adversely affect the entire PV industry. Net loss for the second-quarter of 2012 was $1.8 million, or $0.21 per diluted share, compared with a net income of $0.7 million or $0.08 per diluted share for the second-quarter of 2011.
http://www.spirecorp.com
Starpharma Holdings Ltd (ASX:SPL; OTCQX:SPHRY) and Nufarm Australia (ASX:NUF) signed an agreement under which the parties will apply Starpharma’s Priostar(R) dendrimer technology to develop innovative crop protection formulations for Nufarm’s product portfolio.
The Company released also its annual report and financial results for the year ended 30 June 2012:
• Cash burn (cash outflows before new capital) for the year $9.9M;
• Cash position at end of year $42.8M;
• A$35 million placement and share purchase plan;
• Reported loss $13.7M.
• Full enrolment of the first of Starpharma’s two Phase 3 studies for VivaGel(R) as a treatment for BV; second Phase 3 trial nearing full recruitment.
• FDA and European (EMA) agreement on BV treatment Phase 3 design including Special Protocol Assessment (SPA) by FDA.
• Full recruitment for the Phase 2 clinical trial to investigate the ability of VivaGel® to prevent the recurrence of BV.
• Starpharma’s dendrimers improve efficacy of docetaxel in breast cancer model.
• Expansion of the development program with partner Lilly.
• Priostar(R) dendrimers result in significant improvement in performance of glyphosate (Roundup(R)).
• VivaGel(R)-coated condom agreement signed withAnsell.
• Starpharma elevated to S&P/ASX300 index.
• Signing of an agreement with Nufarm, one of the world’s leading crop protection companies.
http://www.starpharma.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105